MCRB (serestherapeutics.com) Bathi resik saben saham (EPS TTM)

The rolling earnings per share metric in the GURU.Markets system demonstrates profit dynamics, where the -4.87 level reflects the current value. Seres Therapeutics (MCRB) leads in microbiome therapy, having developed VOWST, the first oral drug for combating intestinal infections. The strategy is based on implementing bacterial agents as alternatives to antibiotics. Patent protection of the proprietary platform ensures the company maintains sustainable, long-term market superiority.
Seres (MCRB) - rincian metrik lan laporan keuangan

Seres Therapeutics (MCRB) integration with contract vendors to scale drug production minimizes operational risks, directly impacting the business's bottom-line profitability. This 12-month net income per share snapshot reflects the rolling annual income divided by the number of shares, allowing investors to assess the real efficiency of capitalization and the issuer's fundamental stability over time.